Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on August 31, 2021. The registrant is a Delaware corporation headquartered in Alameda, California, and is classified as an emerging growth company. The report discloses a specific financial event occurring on the date of the report.
Key Financial Metrics
The filing details a specific borrowing event rather than comprehensive financial statements.
- New Debt Obligation: $1.0 million borrowed on August 31, 2021.
- Lender: Juvenescence Limited.
- Facility: Loan Facility Agreement dated August 13, 2019, as amended February 10, 2021.
- Repayment Date: February 14, 2022.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for these metrics.
Material Changes
The primary material change is the increase in the outstanding principal balance of the company's loans under the existing Loan Agreement by $1.0 million. This action utilizes available credit under the facility previously established with Juvenescence Limited.
Outlook, Risks, and Contingencies
Forward-Looking Statements: The company includes standard disclaimers that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially.
Events of Default: The lender may declare the loan immediately due and payable if an Event of Default occurs. Key triggers include:
- Failure to pay amounts due within 10 business days of the due date.
- Failure to perform obligations under the agreement (if remediable, failure to remedy within 10 business days).
- Other indebtedness exceeding $100,000 becoming due early, or indebtedness exceeding $25,000 not being paid when due.
- General cessation of payments, insolvency, liquidation, or appointment of a receiver.
- Material adverse change in the company's financial condition affecting its ability to perform obligations.
- Legal judgments or injunctions materially affecting the business or ability to pay.
Investor Verification Checklist
- Verify the total outstanding principal balance under the Loan Agreement with Juvenescence Limited following this $1.0 million draw.
- Confirm the company's current liquidity position relative to the February 14, 2022, repayment deadline.
- Review the full text of the Loan Agreement (referenced in the filing) for specific covenants and interest rate terms not detailed in this summary.
- Monitor for any subsequent filings regarding additional borrowings or potential defaults under the $100,000/$25,000 cross-default thresholds.